In vivo models for the evaluation of antithrombotics and thrombolytics

Methods in Molecular Biology

Volumn 663, Issue , 2010, Pages 29-107

  Mousa, Shaker A ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Animal models; antithrombotic agents; coronary thrombosis; Folts; genetic models; pharmacodynamics; thrombocytopenia; Wessler

Indexed keywords

ANIMALIA;

CHLORIDE; FERRIC CHLORIDE; FERRIC ION; FIBRINOLYTIC AGENT; THROMBIN;

ANIMAL; ARTICLE; BIOLOGICAL MODEL; BLOOD; CARDIOPULMONARY BYPASS; DISEASE MODEL; DOG; DRUG EFFECT; DRUG SCREENING; ELECTRICITY; FEMALE; FOREIGN BODY; GENETICS; HEMATOLOGIC DISEASE; HEMOSTASIS; HUMAN; LASER; MALE; MECHANICAL STRESS; METHODOLOGY; MOUSE; PHOTOCHEMISTRY; RABBIT; RAT; STENOSIS, OCCLUSION AND OBSTRUCTION; THROMBOSIS;

ANIMALS; CARDIOPULMONARY BYPASS; CHLORIDES; CONSTRICTION, PATHOLOGIC; DISEASE MODELS, ANIMAL; DOGS; DRUG EVALUATION, PRECLINICAL; ELECTRICITY; FEMALE; FERRIC COMPOUNDS; FIBRINOLYTIC AGENTS; FOREIGN BODIES; HEMATOLOGIC DISEASES; HEMOSTASIS; HUMANS; LASERS; MALE; MICE; MODELS, GENETIC; PHOTOCHEMICAL PROCESSES; RABBITS; RATS; STRESS, MECHANICAL; THROMBIN; THROMBOSIS;

EID: 77957684750     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-60761-803-4_2     Document Type: Review

References (289)

1. Didisheim, P. (1972) Animal models useful in the study of thrombosis and antithrombotic agents Prog Hemost Thromb 1, 165-97.
2. Leadley, R.J., Jr., Chi, L., Rebello, S.S., and Gagnon, A. (2000) Contribution of in vivo models of thrombosis to the discovery and development of novel antithrombotic agents J Pharmacol Toxicol Methods 43, 101-16.
3. Wessler, S., Reimer, S.M., and Sheps, M.C. (1959) Biologic assay of a thrombosisinducing activity in human serum J Appl Physiol 14, 943-6.
4. Meuleman, D.G., Hobbelen, P.M., Van Dinther, T.G., Vogel, G.M., Van Boeckel, C.A., and Moelker, H.C. (1991) Antifactor Xa activity and antithrombotic activity in rats of structural analogues of the minimum antithrombin III binding sequence: Discovery of compounds with a longer duration of action than of the natural pentasaccharide Semin Thromb Hemost 17 (Suppl 1), 112-7.
5. Carrie, D., Caranobe, C., Saivin, S., Houin, G., Petitou, M., Lormeau, J.C., Van Boeckel, C., Meuleman, D., and Boneu, B. (1994) Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: Comparison with CY216 Blood 84, 2571-7.
6. Walenga, J.M., Petitou, M., Lormeau, J.C., Samama, M., Fareed, J., and Choay, J. (1987) Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges Thromb Res 46, 187-98.
7. Vlasuk, G.P., Ramjit, D., Fujita, T., Dunwiddie, C.T., Nutt, E.M., Smith, D.E., and Shebuski, R.J. (1991) Comparison of the in vivo anticoagulant properties of standard heparin and the highly selective factor Xa inhibitors antistasin and tick anticoagulant peptide (TAP) in a rabbit model of venous thrombosis Thromb Haemost 65, 257-62.
8. Millet, J., Theveniaux, J., and Brown, N.L. (1994) The venous antithrombotic profile of naroparcil in the rabbit Thromb Haemost 72, 874-9.
9. Callas, D.D., Bacher, P., and Fareed, J. (1995) Studies on the thrombogenic effects of recombinant tissue factor. In vivo versus ex vivo findings Semin Thromb Hemost 21, 166-76.
10. Yeghiazarians, Y., Braunstein, J.B., Askari, A., and Stone, P.H. (2000) Unstable angina pectoris N Engl J Med 342, 101-14.
11. Anderson, H., and Willerson, J. Experimental models of thrombosis. In: Loscalzo, J., and Schafer, A., eds. Thrombosis and Hemorrhage. Boston: Blackwell Scientific; 1994:385-93.
12. Badimon, L. (1997) Models to study thrombotic disorders Thromb Haemost 78, 667-71.
13. Bush, L.R., and Shebuski, R.J. (1990) In vivo models of arterial thrombosis and thrombolysis FASEB J 4, 3087-98.
14. Chi, L., Rebello, S., and Lucchesi, B.R. In vivo models of thrombosis. In: Uprichard, A., and Gallagher, K., eds. Anti-thrombotics. Heidelberg: Springer; 1999:101-27.
15. Gold, H.K., Yasuda, T., Jang, I.K., Guerrero, J.L., Fallon, J.T., Leinbach, R.C., and Collen, D. (1991) Animal models for arterial thrombolysis and prevention of reocclusion. Erythrocyte-rich versus platelet-rich thrombus Circulation 83, IV26-40.
16. Bocan, T.M. (1998) Animal models of atherosclerosis and interpretation of drug intervention studies Curr Pharm Des 4, 37-52.
17. Johnson, G.J., Griggs, T.R., and Badimon, L. (1999) The utility of animal models in the preclinical study of interventions to prevent human coronary artery restenosis: Analysis and recommendations. On behalf of the Subcommittee on Animal, Cellular and Molecular Models of Thrombosis and Haemostasis of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Thromb Haemost 81, 835-43.
18. Hunter, A.J., Green, A.R., and Cross, A.J. (1995) Animal models of acute ischaemic stroke: Can they predict clinically successful neuroprotective drugs? Trends Pharmacol Sci 16, 123-8.
19. Folts, J.D., Crowell, E.B., Jr., and Rowe, G.G. (1976) Platelet aggregation in partially obstructed vessels and its elimination with aspirin Circulation 54, 365-70.
20. Golino, P., Ragni, M., Cirillo, P., D'Andrea, D., Scognamiglio, A., Ravera, A., Buono, C., Ezban, M., Corcione, N., Vigorito, F., Condorelli, M., and Chiariello, M. (1998) Antithrombotic effects of recombinant human, active site-blocked factor VIIa in a rabbit model of recurrent arterial thrombosis Circ Res 82,39-46.
21. Aiken, J.W., Gorman, R.R., and Shebuski, R.J. (1979) Prevention of blockage of partially obstructed coronary arteries with prostacyclin correlates with inhibition of platelet aggregation Prostaglandins 17, 483-94.
22. Aiken, J.W., Shebuski, R.J., Miller, O.V., and Gorman, R.R. (1981) Endogenous prostacyclin contributes to the efficacy of a thromboxane synthetase inhibitor for preventing coronary artery thrombosis J Pharmacol Exp Therap 219, 299-308.
23. Bush, L.R., Campbell, W.B., Buja, L.M., Tilton, G.D., and Willerson, J.T. (1984) Effects of the selective thromboxane synthetase inhibitor dazoxiben on variations in cyclic blood flow in stenosed canine coronary arteries Circulation 69, 1161-70.
24. Folts, J.D., Gallagher, K., and Rowe, G.G. (1982) Blood flow reductions in stenosed canine coronary arteries: Vasospasm or platelet aggregation? Circulation 65, 248-55.
25. Shebuski, R.J., Ramjit, D.R., Bencen, G.H., and Polokoff, M.A. (1989) Characterization and platelet inhibitory activity of bitistatin, a potent arginine-glycine-aspartic acid-containing peptide from the venom of the viper Bitis arietans J Biol Chem 264, 21550-6.
26. Shebuski, R.J., Ramjit, D.R., Sitko, G.R., Lumma, P.K., and Garsky, V.M. (1990) Prevention of canine coronary artery thrombosis with echistatin, a potent inhibitor of platelet aggregation from the venom of the viper, Echis carinatus Thromb Haemost 64, 576-81.
27. Uchida, Y., Yoshimoto, N., and Murao, S. (1975) Cyclic fluctuations in coronary blood pressure and flow induced by coronary artery constriction Jpn Heart J 16, 454-64.
28. Bush, L.R., and Patrick, D.L. (1986) The role of the endothelium in arterial thrombosis and the influence of antithrombotic therapy Drug Devel Res 7, 319-40.
29. Golino, P., Ashton, J.H., Buja, L.M., Rosolowsky, M., Taylor, A.L., McNatt, J., Campbell, W.B., and Willerson, J.T. (1989) Local platelet activation causes vasoconstriction of large epicardial canine coronary arteries in vivo. Thromboxane A2 and serotonin are possible mediators Circulation 79, 154-66.
30. Bush, L.R., Campbell, W.B., Kern, K., Tilton, G.D., Apprill, P., Ashton, J., Schmitz, J., Buja, L.M., and Willerson, J.T. (1984) The effects of alpha 2-adrenergic and serotonergic receptor antagonists on cyclic blood flow alterations in stenosed canine coronary arteries Circ Res 55, 642-52.
31. Bennett, J.S., and Vilaire, G. (1979) Exposure of platelet fibrinogen receptors by ADP and epinephrine J Clin Invest 64, 1393-401.
32. Coller, B.S., and Scudder, L.E. (1985) Inhibition of dog platelet function by in vivo infusion of F(ab)2 fragments of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor Blood 66, 1456-9.
33. Shebuski, R.J., Berry, D.E., Bennett, D.B., Romoff, T., Storer, B.L., Ali, F., and Samanen, J. (1989) Demonstration of Ac-Arg-Gly-Asp-Ser-NH2 as an antiaggregatory agent in the dog by intracoronary administration Thromb Haemost 61, 183-8.
34. Eidt, J.F., Allison, P., Noble, S., Ashton, J., Golino, P., McNatt, J., Buja, L.M., and Willerson, J.T. (1989) Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury J Clin Invest 84, 18-27.
35. Smith, J., and Shebuski, R. (1988) Lack of an inhibitory effect of tissue plasminogen activator (t-PA) on platelet aggregation in vivo FASEB J J2, A1164.
36. Al-Wathiqui, M.H., Hartman, J.C., Brooks, H.L., Gross, G.J., and Warltier, D.C. (1988) Cyclical carotid artery flow reduction in conscious dogs: Effect of a new thromboxane receptor antagonist Am Heart J 116, 1482-7.
37. Gallagher, K.P., Folts, J.D., and Rowe, G.G. (1978) Comparison of coronary arteriograms with direct measurements of stenosed coronary arteries in dogs Am Heart J 95, 338-47.
38. Schumacher, W.A., Heran, C.L., Goldenberg, H.J., Harris, D.N., and Ogletree, M.L. (1989) Magnitude of thromboxane receptor antagonism necessary for antithrombotic activity in monkeys Am J Physiol 256, H726-34.
39. Coller, B.S., Folts, J.D., Scudder, L.E., and Smith, S.R. (1986) Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor in an experimental animal model Blood 68, 783-6.
40. Eidt, J.F., Ashton, J., Golino, P., McNatt, J., Buja, L.M., and Willerson, J.T. (1989) Treadmill exercise promotes cyclic alterations in coronary blood flow in dogs with coronary artery stenoses and endothelial injury J Clin Invest 84, 517-27.
41. O'Neill, W., Topol, E., and Pitt, B. (1988) Coronary thrombolysis for evolving myocardial infarction Prog Cardiovasc Dis 30, 465-83.
42. Folts, J., and Rowe, G. (1974) Cyclical reductions in coronary blood flow in coronary arteries with fixed partial obstruction and their inhibition with aspirin Fed Proc 33.
43. Folts, J.D., and Rowe, G.G. (1988) Epinephrine potentiation of in vivo stimuli reverses aspirin inhibition of platelet thrombus formation in stenosed canine coronary arteries Thromb Res 50, 507-16.
44. Folts, J. (1991) An in vivo model of experimental arterial stenosis, intimal damage, and periodic thrombosis Circulation 83, IV3-14.
45. Just, M., Tripier, D., and Seiffge, D. (1991) Antithrombotic effects of recombinant hirudin in different animal models Haemostasis 21(Suppl 1), 80-7.
46. Apprill, P., Schmitz, J.M., Campbell, W.B., Tilton, G., Ashton, J., Raheja, S., Buja, L.M., and Willerson, J.T. (1985) Cyclic blood flow variations induced by plateletactivating factor in stenosed canine coronary arteries despite inhibition of thromboxane synthetase, serotonin receptors, and alpha-adrenergic receptors Circulation 72, 397-405.
47. Romson, J.L., Hook, B.G., and Lucchesi, B.R. (1983) Potentiation of the antithrombotic effect of prostacyclin by simultaneous administration of aminophylline in a canine model of coronary artery thrombosis J Pharmacol Exp Therap 227, 288-94.
48. Just, M., and Schonafinger, K. (1991) Antithrombotic properties of a novel sydnonimine derivative J Cardiovasc Pharmacol 17(Suppl 3), S121-6.
49. Mousa, S.A., DeGrado, W.F., Mu, D.X., Kapil, R.P., Lucchesi, B.R., and Reilly, T.M. (1996) Oral antiplatelet, antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa antagonist Circulation 93, 537-43.
50. Leadley, R.J., Jr., Kasiewski, C.J., Bostwick, J.S., Bentley, R., Dunwiddie, C.T., and Perrone, M.H. (1998) Inhibition of repetitive thrombus formation in the stenosed canine coronary artery by enoxaparin, but not by unfractionated heparin Arterioscl Thromb Vasc Biol 18, 908-14.
51. Rubsamen, K., and Kirchengast, M. (1998) Thrombin inhibition and intracoronary thrombus formation: Effect of polyethylene glycol-coupled hirudin in the stenosed, locally injured canine coronary artery Coron Artery Dis 9, 35-42.
52. Mehta, J.L., Chen, L., Nichols, W.W., Mattsson, C., Gustafsson, D., and Saldeen, T.G. (1998) Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery J Cardiovasc Pharmacol 31, 345-51.
53. Ikeda, H., Ueyama, T., Murohara, T., Yasukawa, H., Haramaki, N., Eguchi, H., Katoh, A., Takajo, Y., Onitsuka, I., Ueno, T., Tojo, S.J., and Imaizumi, T. (1999) Adhesive interaction between P-selectin and sialyl Lewis(x) plays an important role in recurrent coronary arterial thrombosis in dogs Arterioscl Thromb Vasc Biol 19, 1083-90.
54. Jackson, C.V., Bailey, B.D., and Shetler, T.J. (2000) Pharmacological profile of recombinant, human activated protein C (LY203638) in a canine model of coronary artery thrombosis J Pharmacol Exp Therap 295, 967-71.
55. Romson, J.L., Haack, D.W., and Lucchesi, B.R. (1980) Electrical induction of coronary artery thrombosis in the ambulatory canine: A model for in vivo evaluation of anti-thrombotic agents Thromb Res 17, 841-53.
56. Benedict, C.R., Mathew, B., Rex, K.A., Cartwright, J., Jr., and Sordahl, L.A. (1986) Correlation of plasma serotonin changes with platelet aggregation in an in vivo dog model of spontaneous occlusive coronary thrombus formation Circ Res 58, 58-67.
57. Warltier, D.C., Lamping, K.A., Pelc, L.R., and Gross, G.J. (1987) A canine model of thrombin-induced coronary artery thrombosis: Effects of intracoronary streptokinase on regional myocardial blood flow, contractile function, and infarct size J Pharmacol Methods 18, 305-18.
58. Coller, B.S., Folts, J.D., Smith, S.R., Scudder, L.E., and Jordan, R. (1989) Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor. Correlation with bleeding time, platelet aggregation, and blockade of GPIIb/IIIa receptors Circulation 80, 1766-74.
59. Harbauer, G., Hiller, W., and Hellstern, P. An experimental model of venous thrombosis in the rabbit; test of its usefulness with low-dose heparin. In: L, K., ed. Chirurgisches Forum '84 für experimentelle und klinische Forschung. Berlin: Springer; 1984: 69-72.
60. Just, M. Influence of various agents on experimental thrombosis in the rabbit. In: Wenzel, E., Hellstern, P., Morgenstern, E., Kohler, M., von Blohn, G., eds. Rationelle Therapie und Diagnose von hämorrhagischen und thrombophilen Diathesen. Stuttgart: Schattauer Verlag;1986:4.8-4.95.
61. Bevilacqua, C., Finesso, M., and Prosdocimi, M. (1991) Acute carotid artery occlusive thrombosis and its pharmacological prevention in the rabbit Thromb Res 62, 263-73.
62. Spokas, E.G., and Wun, T.C. (1992) Venous thrombosis produced in the vena cava of rabbits by vascular damage and stasis J Pharmacol Toxicol Methods 27, 225-32.
63. Lyle, E.M., Fujita, T., Conner, M.W., Connolly, T.M., Vlasuk, G.P., and Lynch, J.L., Jr. (1995) Effect of inhibitors of factor Xa or platelet adhesion, heparin, and aspirin on platelet deposition in an atherosclerotic rabbit model of angioplasty injury J Pharmacol Toxicol Methods 33, 53-61.
64. Meng, K. (1975) Tierexperimentelle Untersuchungen zur antithrombotischen Wirkung von Acetylsalicylsäure Therap Ber 47, 69-79.
65. Meng, K., and Seuter, F. (1977) Effect of acetylsalicylic acid on experimentally induced arterial thrombosis in rats Naunyn- Schmiedeberg's Arch Pharmacol 301, 115-9.
66. Seuter, F., Busse, W.D., Meng, K., Hoffmeister, F., Moller, E., and Horstmann, H. (1979) The antithrombotic activity of BAY g 6575 Arzneimittel-Forschung 29, 54-9.
67. Salazar, A.E. (1961) Experimental myocardial infarction. Induction of coronary thrombosis in the intact closed-chest dog Circ Res 9, 1351-6.
68. Schumacher, W.A., Lee, E.C., and Lucchesi, B.R. (1985) Augmentation of streptokinaseinduced thrombolysis by heparin and prostacyclin J Cardiovasc Pharmacol 7, 739-46.
69. van der Giessen, W.J., Harmsen, E., de Tombe, P.P., Hugenholtz, P.G., and Verdouw, P.D. (1988) Coronary thrombolysis with and without nifedipine in pigs Basic Res Cardiol 83, 258-67.
70. Shea, M.J., Driscoll, E.M., Romson, J.L., Pitt, B., and Lucchesi, B.R. (1984) Effect of OKY-1581, a thromboxane synthetase inhibitor, on coronary thrombosis in the conscious dog Eur J Pharmacol 105, 285-91.
71. Simpson, P.J., Smith, C.B., Jr., Rosenthal, G., and Lucchesi, B.R. (1986) Reduction in the incidence of thrombosis by the thromboxane synthetase inhibitor CGS 13080 in a canine model of coronary artery injury J Pharmacol Exp Therap 238, 497-501.
72. Hook, B.G., Schumacher, W.A., Lee, D.L., Jolly, S.R., and Lucchesi, B.R. (1985) Experimental coronary artery thrombosis in the absence of thromboxane A2 synthesis: Evidence for alternate pathways for coronary thrombosis J Cardiovasc Pharmacol 7, 174-81.
73. Schumacher, W.A., and Lucchesi, B.R. (1983) Effect of the thromboxane synthetase inhibitor UK-37,248 (dazoxiben) upon platelet aggregation, coronary artery thrombosis and vascular reactivity J Pharmacol Exp Therap 227, 790-6.
74. Fitzgerald, D.J., Fragetta, J., and FitzGerald, G.A. (1988) Prostaglandin endoperoxides modulate the response to thromboxane synthase inhibition during coronary thrombosis J Clin Invest 82, 1708-13.
75. Mickelson, J.K., Simpson, P.J., and Lucchesi, B.R. (1989) Antiplatelet monoclonal F(ab)2 antibody directed against the platelet GPIIb/IIIa receptor complex prevents coronary artery thrombosis in the canine heart J Mol Cell Cardiol 21, 393-405.
76. Shebuski, R.J., Smith, J.M., Jr., Storer, B.L., Granett, J.R., and Bugelski, P.J. (1988) Influence of selective endoperoxide/ thromboxane A2 receptor antagonism with sulotroban on lysis time and reocclusion rate after tissue plasminogen activatorinduced coronary thrombolysis in the dog J Pharmacol Exp Therap 246, 790-6.
77. van der Giessen, W.J., Zijlstra, F.J., Berk, L., and Verdouw, P.D. (1988) The effect of the thromboxane receptor antagonist BM 13.177 on experimentally induced coronary artery thrombosis in the pig Eur J Pharmacol 147, 241-8.
78. Patterson, E., Eller, B.T., Abrams, G.D., Vasiliades, J., and Lucchesi, B.R. (1983) Ventricular fibrillation in a conscious canine preparation of sudden coronary death-prevention by short- and long-term amiodarone administration Circulation 68, 857-64.
79. Lefkovits, J., Malycky, J.L., Rao, J.S., Hart, C.E., Plow, E.F., Topol, E.J., and Nicolini, F.A. (1996) Selective inhibition of factor Xa is more efficient than factor VIIa-tissue factor complex blockade at facilitating coronary thrombolysis in the canine model J Am Coll Cardiol 28, 1858-65.
80. Lynch, J.J., Jr., Sitko, G.R., Mellott, M.J., Nutt, E.M., Lehman, E.D., Friedman, P.A., Dunwiddie, C.T., and Vlasuk, G.P. (1994) Maintenance of canine coronary artery patency following thrombolysis with front loaded plus low dose maintenance conjunctive therapy. A comparison of factor Xa versus thrombin inhibition Cardiovasc Res 28, 78-85.
81. Nicolini, F.A., Lee, P., Rios, G., Kottke- Marchant, K., and Topol, E.J. (1994) Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis Circulation 89, 1802-9.
82. Sitko, G.R., Ramjit, D.R., Stabilito, II, Lehman, D., Lynch, J.J., and Vlasuk, G.P. (1992) Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis Circulation 85, 805-15.
83. Waxman, L., Smith, D.E., Arcuri, K.E., and Vlasuk, G.P. (1990) Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa Science 248, 593-6.
84. Lutz, B.R., Fulton, G.P., and Akers, R.P. (1951) White thromboembolism in the hamster cheek pouch after trauma, infection and neoplasia Circulation 3, 339-51.
85. Sawyer, P.N., and Pate, J.W. (1953) Bioelectric phenomena as an etiologic factor in intravascular thrombosis Am J Physiol 175, 103-7.
86. Sawyer, P.N., Pate, J.W., and Weldon, C.S. (1953) Relations of abnormal and injury electric potential differences to intravascular thrombosis Am J Physiol 175, 108-12.
87. Hladovec, J. (1971) Experimental arterial thrombosis in rats with continuous registration Thromb Diath Haemorrh 26, 407-10.
88. Philp, R.B., Francey, I., and Warren, B.A. (1978) Comparison of antithrombotic activity of heparin, ASA, sulfinpyrazone and VK 744 in a rat model of arterial thrombosis Haemostasis 7, 282-93.
89. Rote, W.E., Mu, D.X., Roncinske, R.A., Frelinger, A.L., 3rd, and Lucchesi, B.R. (1993) Prevention of experimental carotid artery thrombosis by applaggin J Pharmacol Exp Therap 267, 809-14.
90. Rote, W.E., Davis, J.H., Mousa, S.A., Reilly, T.M., and Lucchesi, B.R. (1994) Antithrombotic effects of DMP 728, a platelet GPIIb/IIIa receptor antagonist, in a canine model of arterial thrombosis J Cardiovasc Pharmacol 23, 681-9.
91. Schumacher, W.A., Heran, C.L., and Steinbacher, T.E. (1996) Low-molecularweight heparin (fragmin) and thrombin active-site inhibitor (argatroban) compared in experimental arterial and venous thrombosis and bleeding time J Cardiovasc Pharmacol 28, 19-25.
92. Guarini, S. (1996) A highly reproducible model of arterial thrombosis in rats J Pharmacol Toxicol Methods 35, 101-5.
93. Kurz, K.D., Main, B.W., and Sandusky, G.E. (1990) Rat model of arterial thrombosis induced by ferric chloride Thromb Res 60, 269-80.
94. Deschenes, I., Finkle, C.D., and Winocour, P.D. (1998) Effective use of BCH-2763, a new potent injectable direct thrombin inhibitor, in combination with tissue plasminogen activator (tPA) in a rat arterial thrombolysis model Thromb Haemost 80, 186-91.
95. Elg, M., Gustafsson, D., and Carlsson, S. (1999) Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat Thromb Res 94, 187-97.
96. Schumacher, W.A., Heran, C.L., Steinbacher, T.E., Youssef, S., and Ogletree, M.L. (1993) Superior activity of a thromboxane receptor antagonist as compared with aspirin in rat models of arterial and venous thrombosis J Cardiovasc Pharmacol 22, 526-33.
97. Roesken, F., Ruecker, M., Vollmar, B., Boeckel, N., Morgenstern, E., and Menger, M.D. (1997) A new model for quantitative in vivo microscopic analysis of thrombus formation and vascular recanalisation: The ear of the hairless (hr/hr) mouse Thromb Haemost 78, 1408-14.
98. Saniabadi, A.R., Umemura, K., Matsumoto, N., Sakuma, S., and Nakashima, M. (1995) Vessel wall injury and arterial thrombosis induced by a photochemical reaction Thromb Haemost 73, 868-72.
99. Hokamura, K., Umemura, K., Nakamura, N., Watanabe, M., Takashima, T., and Nakashima, M. (1998) Effect of lipo-proprostaglandin E1, AS-013 on rat inner ear microcirculatory thrombosis Prostaglandins Leukot Essent Fatty Acids 59, 203-7.
100. Reimann-Hunziger, G. (1944) Über experimentelle Thrombose und ihre Behandlung mit Heparin Schweiz Med Wschr 74, 66-9.
101. Broersma, R.J., Kutcher, L.W., and Heminger, E.F. (1991) The effect of thrombin inhibition in a rat arterial thrombosis model Thromb Res 64, 405-12.
102. van Giezen, J.J., Wahlund, G., Nerme, and Abrahamsson, T. (1997) The Fab-fragment of a PAI-1 inhibiting antibody reduces thrombus size and restores blood flow in a rat model of arterial thrombosis Thromb Haemost 77, 964-9.
103. Shebuski, R.J., Storer, B.L., and Fujita, T. (1988) Effect of thromboxane synthase inhibition on the thrombolytic action of tissuetype plasminogen activator in a rabbit model of peripheral arterial thrombosis Thromb Res 52, 381-92.
104. Gold, H.K., Fallon, J.T., Yasuda, T., Leinbach, R.C., Khaw, B.A., Newell, J.B., Guerrero, J.L., Vislosky, F.M., Hoyng, C.F., and Grossbard, E., et al. (1984) Coronary thrombolysis with recombinant human tissue-type plasminogen activator Circulation 70, 700-7.
105. Collen, D., Stassen, J.M., and Verstraete, M. (1983) Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration J Clin Invest 71, 368-76.
106. Kopia, G.A., Kopaciewicz, L.J., and Ruffolo, R.R., Jr. (1988) Coronary thrombolysis with intravenous streptokinase in the anesthetized dog: A dose-response study J Pharmacol Exp Therap 244, 956-62.
107. Gold, H.K., Leinbach, R.C., Garabedian, H.D., Yasuda, T., Johns, J.A., Grossbard, E.B., Palacios, I., and Collen, D. (1986) Acute coronary reocclusion after thrombolysis with recombinant human tissuetype plasminogen activator: Prevention by a maintenance infusion Circulation 73, 347-52.
108. Gold, H.K., Coller, B.S., Yasuda, T., Saito, T., Fallon, J.T., Guerrero, J.L., Leinbach, R.C., Ziskind, A.A., and Collen, D. (1988) Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation Circulation 77, 670-7.
109. Goldberg, R.K., Levine, S., and Fenster, P.E. (1985) Management of patients after thrombolytic therapy for acute myocardial infarction Clin Cardiol 8, 455-9.
110. Coller, B.S., Peerschke, E.I., Scudder, L.E., and Sullivan, C.A. (1983) A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa J Clin Invest 72, 325-38.
111. Yasuda, T., Gold, H.K., Fallon, J.T., Leinbach, R.C., Guerrero, J.L., Scudder, L.E., Kanke, M., Shealy, D., Ross, M.J., and Collen, D., et al. (1988) Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs J Clin Invest 81, 1284-91.
112. Weichert, W., and Breddin, H.K. (1988) Effect of low-molecular-weight heparins on laser-induced thrombus formation in rat mesenteric vessels Haemostasis 18(Suppl 3), 55-63.
113. Arfors, K.E., Dhall, D.P., Engeset, J., Hint, H., Matheson, N.A., and Tangen, O. (1968) Biolaser endothelial trauma as a means of quantifying platelet activity in vivo Nature 218, 887-8.
114. Herrmann, K.S. (1983) Platelet aggregation induced in the hamster cheek pouch by a photochemical process with excited fluorescein isothiocyanate-dextran Microvasc Res 26, 238-49.
115. Seiffge, D., and Kremer, E. (1984) Antithrombotic effects of pentoxifylline on laser-induced thrombi in rat mesenteric arteries IRCS Med Sci 12, 91-2.
116. Seiffge, D., and Kremer, E. (1986) Influence of ADP, blood flow velocity, and vessel diameter on the laser-induced thrombus formation Thromb Res 42, 331-41.
117. Seiffge, D., and Weithmann, K.U. (1987) Surprising effects of the sequential administration of pentoxifylline and low dose acetylsalicylic acid on thrombus formation Thromb Res 46, 371-83.
118. Weichert, W., Pauliks, V., and Breddin, H.K. (1983) Laser-induced thrombi in rat mesenteric vessels and antithrombotic drugs Haemostasis 13, 61-71.
119. Rosenblum, W.I., and El-Sabban, F. (1977) Platelet aggregation in the cerebral microcirculation: Effect of aspirin and other agents Circ Res 40, 320-8.
120. Matsuno, H., Uematsu, T., Nagashima, S., and Nakashima, M. (1991) Photochemically induced thrombosis model in rat femoral artery and evaluation of effects of heparin and tissue-type plasminogen activator with use of this model J Pharmacol Methods 25, 303-17.
121. Stone, P., and Lord, J.W., Jr. (1951) An experimental study of the thrombogenic properties of magnesium and magnesiumaluminum wire in the dog's aorta Surgery 30, 987-93.
122. Mellott, M.J., Stranieri, M.T., Sitko, G.R., Stabilito, I.I., Lynch Jr, J.J., and Vlasuk, G.P. (1993) Enhancement of recombinant tissue plasminogen activator-induced reperfusion by recombinant tick anticoagulant peptide, a selective factor Xa inhibitor, in a canine model of femoral arterial thrombosis Fibrinolysis 7, 195-202.
123. Rubsamen, K., and Hornberger, W. (1996) Prevention of early reocclusion after thrombolysis of copper coil-induced thrombi in the canine carotid artery: Comparison of PEGhirudin and unfractionated heparin Thromb Haemost 76, 105-10.
124. Kumada, T., Ishihara, M., Ogawa, H., and Abiko, Y. (1980) Experimental model of venous thrombosis in rats and effect of some agents Thromb Res 18, 189-203.
125. Bernat, A., Vallee, E., and Maffrand, J. (1986) A simple experimental model of thrombolysis in the rat: Effect of urokinase and of the complex human plasminogenstreptokinase Thromb Res 44, 112.
126. Hergrueter, C.A., Handren, J., Kersh, R., and May, J.W., Jr. (1988) Human recombinant tissue type plasminogen activator and its effect on microvascular thrombosis in the rabbit Plast Reconstruct Surg 81, 418-24.
127. Jang, I.K., Gold, H.K., Ziskind, A.A., Fallon, J.T., Holt, R.E., Leinbach, R.C., May, J.W., and Collen, D. (1989) Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis Circulation 79, 920-8.
128. Jang, I.K., Gold, H.K., Ziskind, A.A., Leinbach, R.C., Fallon, J.T., and Collen, D. (1990) Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition Circulation 81, 219-25.
129. Kaiser, B., and Fareed, J. (1996) Recombinant full-length tissue factor pathway inhibitor (TFPI) prevents thrombus formation and rethrombosis after lysis in a rabbit model of jugular vein thrombosis Thromb Haemost 76, 615-20.
130. Kaiser, B., Simon, A., and Markwardt, F. (1990) Antithrombotic effects of recombinant hirudin in experimental angioplasty and intravascular thrombolysis Thromb Haemost 63, 44-7.
131. Katsuragawa, M., Fujiwara, H., Kawamura, A., Htay, T., Yoshikuni, Y., Mori, K., and Sasayama, S. (1993) An animal model of coronary thrombosis and thrombolysis- comparisons of vascular damage and thrombus formation in the coronary and femoral arteries after balloon angioplasty Jpn Circ J 57, 1000-6.
132. Kaiser, B., and Markwardt, F. (1986) Experimental studies on the antithrombotic action of a highly effective synthetic thrombin inhibitor Thromb Haemost 55, 194-6.
133. Heras, M., Chesebro, J.H., Penny, W.J., Bailey, K.R., Lam, J.Y., Holmes, D.R., Reeder, G.S., Badimon, L., and Fuster, V. (1988) Importance of adequate heparin dosage in arterial angioplasty in a porcine model Circulation 78, 654-60.
134. Harker, L.A. (1987) Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty Am J Cardiol 60, 20B-8B.
135. Rowntree, L., and Shionoya, T. (1927) Studies in extracorporeal thrombosis. I. A method for the direct observation of extracorporal thrombus formation. II. Thrombosis formation in normal blood in the extracorporeal vascular loop. III. Effects of certain anticoagulants (heparin and hirudin) on extracorporeal thrombosis and on the mechanism of thrombus formation J ExpMed 46, 7-26.
136. Knabb, R.M., Kettner, C.A., Timmermans, P.B., and Reilly, T.M. (1992) In vivo characterization of a new synthetic thrombin inhibitor Thromb Haemost 67, 56-9.
137. Hara, T., Yokoyama, A., Tanabe, K., Ishihara, H., and Iwamoto, M. (1995) DX- 9065a, an orally active, specific inhibitor of factor Xa, inhibits thrombosis without affecting bleeding time in rats Thromb Haemost 74, 635-9.
138. Scott, N.A., Nunes, G.L., King, S.B., 3rd, Harker, L.A., and Hanson, S.R. (1994) Local delivery of an antithrombin inhibits platelet-dependent thrombosis Circulation 90, 1951-5.
139. Best, C.H., Cowan, C., and Maclean, D.L. (1938) Heparin and the formation of white thrombi J Physiol 92, 20-31.
140. Yokoyama, T., Kelly, A.B., Marzec, U.M., Hanson, S.R., Kunitada, S., and Harker, L.A. (1995) Antithrombotic effects of orally active synthetic antagonist of activated factor X in nonhuman primates Circulation 92, 485-91.
141. Hollenbach, S., Wong, A., Ku, P., Needham, K., Lin, P.H., and Sinha, U. (1995) Efficacy of FXa inhibitors in a rabbit model of venous thrombosis Circulation 92, I486-7.
142. Hollenbach, S., Sinha, U., Lin, P.H., Needham, K., Frey, L., Hancock, T., Wong, A., and Wolf, D. (1994) A comparative study of prothrombinase and thrombin inhibitors in a novel rabbit model of non-occlusive deep vein thrombosis Thromb Haemost 71, 357-62.
143. Gryglewski, R.J., Korbut, R., Ocetkiewicz, A., and Stachura, J. (1978) In vivo method for quantitation for anti-platelet potency of drugs Naunyn-Schmiedeberg's Arch Pharmacol 302, 25-30.
144. Wessler, S. (1952) Studies in intravascular coagulation. I. Coagulation changes in isolated venous segments J Clin Invest 31, 1011-4.
145. Wessler, S. (1953) Studies in intravascular coagulation. II. A comparison of the effect of dicumarol and heparin on clot formation in isolated venous segments J Clin Invest 32, 650-4.
146. Wessler, S. (1955) Studies in intravascular coagulation. III. The pathogenesis of seruminduced venous thrombosis J Clin Invest 34, 647-51.
147. Wessler, S., Ballon, J.D., and Katz, J.H. (1957) Studies in intravascular coagulation. V. A distinction between the anticoagulant and antithrombotic effects of dicumarol N Engl J Med 256, 1223-5.
148. Wessler, S., and Morris, L.E. (1955) Studies in intravascular coagulation. IV. The effect of heparin and dicumarol on serum-induced venous thrombosis Circulation 12, 553-6.
149. Fareed, J., Walenga, J.M., Kumar, A., and Rock, A. (1985) A modified stasis thrombosis model to study the antithrombotic actions of heparin and its fractions Semin Thromb Hemost 11, 155-75.
150. Aronson, D.L., and Thomas, D.P. (1985) Experimental studies on venous thrombosis: Effect of coagulants, procoagulants and vessel contusion Thromb Haemost 54, 866-70.
151. Breddin, H.K. (1989) Thrombosis and Virchow's triad: What is established? Semin Thromb Hemost 15, 237-9.
152. Levi, M., Biemond, B.J., van Zonneveld, A.J., ten Cate, J.W., and Pannekoek, H. (1992) Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis Circulation 85, 305-12.
153. Biemond, B.J., Friederich, P.W., Levi, M., Vlasuk, G.P., Buller, H.R., and ten Cate, J.W. (1996) Comparison of sustained antithrombotic effects of inhibitors of thrombin and factor Xa in experimental thrombosis Circulation 93, 153-60.
154. Herbert, J.M., Bernat, A., Dol, F., Herault, J.P., Crepon, B., and Lormeau, J.C. (1996) DX 9065A a novel, synthetic, selective and orally active
155. Sato, K., Kawasaki, T., Hisamichi, N., Taniuchi, Y., Hirayama, F., Koshio, H., and Matsumoto, Y. (1998) Antithrombotic effects of YM-60828, a newly synthesized factor Xa inhibitor, in rat thrombosis models and its effects on bleeding time Br J Pharmacol 123, 92-6.
156. Yamazaki, M., Asakura, H., Aoshima, K., Saito, M., Jokaji, H., Uotani, C., Kumabashiri, I., Morishita, E., Ikeda, T., and Matsuda, T. (1994) Effects of DX-9065a, an orally active, newly synthesized and specific inhibitor of factor Xa, against experimental disseminated intravascular coagulation in rats Thromb Haemost 72, 392-6.
157. Fu, K., Izquierdo, R., Vandevender, D., Warpeha, R.L., Wolf, H., and Fareed, J. (1997) Topical application of low molecular weight heparin in a rabbit traumatic anastomosis model Thromb Res 86, 355-61.
158. Korompilias, A.V., Chen, L.E., Seaber, A.V., and Urbaniak, J.R. (1997) Antithrombotic potencies of enoxaparin in microvascular surgery: Influence of dose and administration methods on patency rate of crushed arterial anastomoses J Hand Surg 22, 540-6.
159. Stockmans, F., Stassen, J.M., Vermylen, J., Hoylaerts, M.F., and Nystrom, A. (1997) A technique to investigate mural thrombus formation in small arteries and veins: I. Comparative morphometric and histological analysis Ann Plast Surg 38, 56-62.
160. van Wyk, V., Neethling, W.M., Badenhorst, P.N., and Kotze, H.F. (1998) r-Hirudin inhibits platelet-dependent thrombosis during cardiopulmonary bypass in baboons J Cardiovasc Surg 39, 633-9.
161. Dewanjee, M.K., Wu, S.M., Kapadvanjwala, M., De, D., Dewanjee, S., Novak, S., Hsu, L.C., Perryman, R.A., Serafini, A.N., Sfakianakis, G.N., Duncan, R.C., Dietrich, W.D., and Horton, A.F. (1996) Reduction of platelet thrombi and emboli by L-arginine during cardiopulmonary bypass in a pig model J Thromb Thrombolysis 3, 343-60.
162. Henny, C.P., Ten Cate, H., Ten Cate, J.W., Moulijn, A.C., Sie, T.H., Warren, P., and Buller, H.R. (1985) A randomized blind study comparing standard heparin and a new low molecular weight heparinoid in cardiopulmonary bypass surgery in dogs J Lab Clin Med 106, 187-96.
163. Murray, W. A preliminary study of low molecular weight heparin in aortocoronay bypass surgery. In: Murray, W., ed. Low Molecular Weight Heparin in Surgical Practice (Master of Surgery Thesis). London: University of London;1985:266.
164. Badimon, L., and Badimon, J.J. (1989) Mechanisms of arterial thrombosis in nonparallel streamlines: Platelet thrombi grow on the apex of stenotic severely injured vessel wall. Experimental study in the pig model J Clin Invest 84, 1134-44.
165. Wysokinski,W., McBane, R., Chesebro, J.H., and Owen, W.G. (1996) Reversibility of platelet thrombosis in vivo. Quantitative analysis in porcine carotid arteries Thromb Haemost 76, 1108-13.
166. Dangas, G., Badimon, J.J., Coller, B.S., Fallon, J.T., Sharma, S.K., Hayes, R.M., Meraj, P., Ambrose, J.A., and Marmur, J.D. (1998) Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition: Implications for a potential anticoagulant effect of abciximab Arterioscler Thromb Vasc Biol 18, 1342-9.
167. Ørvim, U., Barstad R.M., Vlasuk., G.P., and Sakariassen, K.S. (1995) Effect of selective factor Xa inhibition on arterial thrombus formation triggered by tissue factor/factor VIIa or collagen in an ex vivo model of shear-dependent human thrombogenesis Arterioscler Thromb Vasc Biol 15, 2188-94.
168. Angelillo-Scherrer, A., de Frutos, P., Aparicio, C., Melis, E., Savi, P., Lupu, F., Arnout, J., Dewerchin, M., Hoylaerts, M., Herbert, J., Collen, D., Dahlback, B., and Carmeliet, P. (2001) Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis Nat Med 7, 215-21.
169. Yang, J., Wu, J., Kowalska, M.A., Dalvi, A., Prevost, N., O'Brien, P.J., Manning, D., Poncz, M., Lucki, I., Blendy, J.A., and Brass, L.F. (2000) Loss of signaling through the G protein, Gz, results in abnormal platelet activation and altered responses to psychoactive drugs Proc Natl Acad Sci USA 97, 9984-9.
170. Volkl, K.P., and Dierichs, R. (1986) Effect of intravenously injected collagenase on the concentration of circulating platelets in rats Thromb Res 42, 11-20.
171. Oyekan, A.O., and Botting, J.H. (1986) A minimally invasive technique for the study of intravascular platelet aggregation in anesthetized rats J Pharmacol Methods 15, 271-7.
172. Smith, D., Sanjar, S., Herd, C., and Morley, J. (1989) In vivo method for the assessment of platelet accumulation J Pharmacol Methods 21, 45-59.
173. Dottl, K., and Ripke, O. Blutgerinnung und Blutungszeit. In: Medizin und Chemie. Leverkusen: Bayer;1936:267-73.
174. Dejana, E., Callioni, A., Quintana, A., and de Gaetano, G. (1979) Bleeding time in laboratory animals. II-A comparison of different assay conditions in rats Thromb Res 15, 191-7.
175. Minsker, D.H., and Kling, P.J. (1977) Bleeding time in rats is prolonged by aspirin Thromb Res 10, 619-22.
176. Stella, L., Donati, M.B., and de Gaetano, G. (1975) Bleeding time in laboratory animals I. Aspirin does not prolong bleeding time in rats Thromb Res 7, 709-16.
177. Butler, K.D., Maguire, E.D., Smith, J.R., Turnbull, A.A.,Wallis, R.B., andWhite, A.M. (1982) Prolongation of rat tail bleeding time caused by oral doses of a thromboxane synthetase inhibitor which have little effect on platelet aggregation Thromb Haemost 47, 46-9.
178. Zawilska, K.M., Born, G.V., and Begent, N.A. (1982) Effect of ADP-utilizing enzymes on the arterial bleeding time in rats and rabbits Br J Haematol 50, 317-25.
179. Forsythe, L.T., and Willis, S.E. (1989) Evaluating oral mucosa bleeding times in healthy dogs using a spring-loaded device Can Veter J 30, 344-5.
180. Klement, P., Liao, P., Hirsh, J., Johnston, M., and Weitz, J.I. (1998) Hirudin causes more bleeding than heparin in a rabbit ear bleeding model J Lab Clin Med 132, 181-5.
181. Brassard, J.A., and Meyers, K.M. (1991) Evaluation of the buccal bleeding time and platelet glass bead retention as assays of hemostasis in the dog: The effects of acetylsalicylic acid, warfarin and von Willebrand factor deficiency Thromb Haemost 65, 191-5.
182. Lind, S.E. (1991) The bleeding time does not predict surgical bleeding Blood 77, 2547-52.
183. Giles, A.R., Tinlin, S., and Greenwood, R. (1982) A canine model of hemophilic (factor VIII: C deficiency) bleeding Blood 60, 727-30.
184. Carmeliet, P., and Collen, D. New developments in the molecular biology of coagulation and fibrinolysis. In: Handbook of Experimental Pharmacology, Vol 132, Antithrombotics. Berlin: Springer- Verlag;1999:41-76.
185. Pearson, J., and Ginsburg, D. Use of transgenic mice in the study of thrombosis and hemostasis. In: Handbook of Experimental Pharmacology, Vol 132, Antithrombotics. Berlin: Springer-Verlag; 1999:157-74.
186. Bi, L., Sarkar, R., Naas, T., Lawler, A.M., Pain, J., Shumaker, S.L., Bedian, V., and Kazazian, H.H., Jr. (1996) Further characterization of factor VIII-deficient mice created by gene targeting: RNA and protein studies Blood 88, 3446-50.
187. Denis, C., Methia, N., Frenette, P.S., Rayburn, H., Ullman-Cullere, M., Hynes, R.O., and Wagner, D.D. (1998) A mouse model of severe von Willebrand disease: Defects in hemostasis and thrombosis Proc Natl Acad Sci USA 95, 9524-9.
188. Hodivala-Dilke, K.M., McHugh, K.P., Tsakiris, D.A., Rayburn, H., Crowley, D., Ullman-Cullere, M., Ross, F.P., Coller, B.S., Teitelbaum, S., and Hynes, R.O. (1999) Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival J Clin Invest 103, 229-38.
189. Wang, L., Zoppe, M., Hackeng, T.M., Griffin, J.H., Lee, K.F., and Verma, I.M. (1997) A factor IX-deficient mouse model for hemophilia B gene therapy Proc Natl Acad Sci USA 94, 11563-6.
190. Offermanns, S., Toombs, C.F., Hu, Y.H., and Simon, M.I. (1997) Defective platelet activation in G alpha(q)-deficient mice Nature 389, 183-6.
191. Law, D.A., DeGuzman, F.R., Heiser, P., Ministri-Madrid, K., Killeen, N., and Phillips, D.R. (1999) Integrin cytoplasmic tyrosine motif is required for outside-in alphaIIbbeta3 signalling and platelet function Nature 401, 808-11.
192. Kahn, M.L., Zheng, Y.W., Huang, W., Bigornia, V., Zeng, D., Moff, S., Farese, R.V., Jr., Tam, C., and Coughlin, S.R. (1998) A dual thrombin receptor system for platelet activation Nature 394, 690-4.
193. Leon, C., Hechler, B., Freund, M., Eckly, A., Vial, C., Ohlmann, P., Dierich, A., LeMeur, M., Cazenave, J.P., and Gachet, C. (1999) Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice J Clin Invest 104, 1731-7.
194. Subramaniam, M., Frenette, P.S., Saffaripour, S., Johnson, R.C., Hynes, R.O., and Wagner, D.D. (1996) Defects in hemostasis in P-selectin-deficient mice Blood 87, 1238-42.
195. Thomas, D.W., Mannon, R.B., Mannon, P.J., Latour, A., Oliver, J.A., Hoffman, M., Smithies, O., Koller, B.H., and Coffman, T.M. (1998) Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2 J Clin Invest 102, 1994-2001.
196. Bugge, T.H., Flick, M.J., Daugherty, C.C., and Degen, J.L. (1995) Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction Genes Develop 9, 794-807.
197. Ploplis, V.A., Carmeliet, P., Vazirzadeh, S., Van Vlaenderen, I., Moons, L., Plow, E.F., and Collen, D. (1995) Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice Circulation 92, 2585-93.
198. Carmeliet, P., Schoonjans, L., Kieckens, L., Ream, B., Degen, J., Bronson, R., De Vos, R., van den Oord, J.J., Collen, D., and Mulligan, R.C. (1994) Physiological consequences of loss of plasminogen activator gene function in mice Nature 368, 419-24.
199. Christie, P.D., Edelberg, J.M., Picard, M.H., Foulkes, A.S., Mamuya, W., Weiler-Guettler, H., Rubin, R.H., Gilbert, P., and Rosenberg, R.D. (1999) A murine model of myocardial microvascular thrombosis J Clin Invest 104, 533-9.
200. Carmeliet, P., Stassen, J.M., Schoonjans, L., Ream, B., van den Oord, J.J., De Mol, M., Mulligan, R.C., and Collen, D. (1993) Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis J Clin Invest 92, 2756-60.
201. Bugge, T.H., Xiao, Q., Kombrinck, K.W., Flick, M.J., Holmback, K., Danton, M.J., Colbert, M.C., Witte, D.P., Fujikawa, K., Davie, E.W., and Degen, J.L. (1996) Fatal embryonic bleeding events in mice lacking tissue factor, the cell-associated initiator of blood coagulation Proc Natl Acad Sci USA 93, 6258-63.
202. Carmeliet, P., Mackman, N., Moons, L., Luther, T., Gressens, P., Van Vlaenderen, I., Demunck, H., Kasper, M., Breier, G., Evrard, P., Muller, M., Risau, W., Edgington, T., and Collen, D. (1996) Role of tissue factor in embryonic blood vessel development Nature 383, 73-5.
203. Toomey, J.R., Kratzer, K.E., Lasky, N.M., Stanton, J.J., and Broze, G.J., Jr. (1996) Targeted disruption of the murine tissue factor gene results in embryonic lethality Blood 88, 1583-7.
204. Huang, Z.F., Higuchi, D., Lasky, N., and Broze, G.J., Jr. (1997) Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice Blood 90, 944-51.
205. Healy, A.M., Rayburn, H.B., Rosenberg, R.D., and Weiler, H. (1995) Absence of the blood-clotting regulator thrombomodulin causes embryonic lethality in mice before development of a functional cardiovascular system Proc Natl Acad Sci USA 92, 850-4.
206. Connolly, A.J., Ishihara, H., Kahn, M.L., Farese, R.V., Jr., and Coughlin, S.R. (1996) Role of the thrombin receptor in development and evidence for a second receptor Nature 381, 516-9.
207. Cui, J., O'Shea, K.S., Purkayastha, A., Saunders, T.L., and Ginsburg, D. (1996) Fatal haemorrhage and incomplete block to embryogenesis in mice lacking coagulation factor V Nature 384, 66-8.
208. Lin, H.F., Maeda, N., Smithies, O., Straight, D.L., and Stafford, D.W. (1997) A coagulation factor IX-deficient mouse model for human hemophilia B Blood 90, 3962-6.
209. Kung, S.H., Hagstrom, J.N., Cass, D., Tai, S.J., Lin, H.F., Stafford, D.W., and High, K.A. (1998) Human factor IX corrects the bleeding diathesis of mice with hemophilia B Blood 91, 784-90.
210. Evans, J.P., Brinkhous, K.M., Brayer, G.D., Reisner, H.M., and High, K.A. (1989) Canine hemophilia B resulting from a point mutation with unusual consequences Proc Natl Acad Sci USA 86, 10095-9.
211. Herzog, R.W., Yang, E.Y., Couto, L.B., Hagstrom, J.N., Elwell, D., Fields, P.A., Burton, M., Bellinger, D.A., Read, M.S., Brinkhous, K.M., Podsakoff, G.M., Nichols, T.C., Kurtzman, G.J., and High, K.A. (1999) Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adenoassociated viral vector Nat Med 5, 56-63.
212. Kawasaki T., Dewerchin M., Lijnen H.R., Vermylen J., Hoylaerts M.F. (2000) Vascular release of plasminogen activator inhibitor- 1 impairs fibrinolysis during acute arterial thrombosis in mice. Blood 96, 153-60.
213. Waugh, J.M., Yuksel, E., Li, J., Kuo, M.D., Kattash, M., Saxena, R., Geske, R., Thung, S.N., Shenaq, S.M., and Woo, S.L. (1999) Local overexpression of thrombomodulin for in vivo prevention of arterial thrombosis in a rabbit model Circ Res 84, 84-92.
214. Waugh, J.M., Kattash, M., Li, J., Yuksel, E., Kuo, M.D., Lussier, M., Weinfeld, A.B., Saxena, R., Rabinovsky, E.D., Thung, S., Woo, S.L., and Shenaq, S.M. (1999) Gene therapy to promote thromboresistance: Local overexpression of tissue plasminogen activator to prevent arterial thrombosis in an in vivo rabbit model Proc Natl Acad Sci USA 96, 1065-70.
215. Zoldhelyi, P., McNatt, J., Shelat, H.S., Yamamoto, Y., Chen, Z.Q., and Willerson, J.T. (2000) Thromboresistance of ballooninjured porcine carotid arteries after local gene transfer of human tissue factor pathway inhibitor Circulation 101, 289-95.
216. Vassalli, G., and Dichek, D.A. (1997) Gene therapy for arterial thrombosis Cardiovasc Res 35, 459-69.
217. Suh, T.T., Holmback, K., Jensen, N.J., Daugherty, C.C., Small, K., Simon, D.I., Potter, S., and Degen, J.L. (1995) Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice Genes Develop 9, 2020-33.
218. Yang, T.L., Cui, J., Taylor, J.M., Yang, A., Gruber, S.B., and Ginsburg, D. (2000) Rescue of fatal neonatal hemorrhage in factor V deficient mice by low level transgene expression Thromb Haemost 83, 70-7.
219. Rosen, E.D., Chan, J.C., Idusogie, E., Clotman, F., Vlasuk, G., Luther, T., Jalbert, L.R., Albrecht, S., Zhong, L., Lissens, A., Schoonjans, L., Moons, L., Collen, D., Castellino, F.J., and Carmeliet, P. (1997) Mice lacking factor VII develop normally but suffer fatal perinatal bleeding Nature 390, 290-4.
220. Bi, L., Lawler, A.M., Antonarakis, S.E., High, K.A., Gearhart, J.D., and Kazazian, H.H., Jr. (1995) Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A Nat Genet 10, 119-21.
221. Kundu, R.K., Sangiorgi, F., Wu, L.Y., Kurachi, K., Anderson, W.F., Maxson, R., and Gordon, E.M. (1998) Targeted inactivation of the coagulation factor IX gene causes hemophilia B in mice Blood 92, 168-74.
222. Dewerchin, M., Liang, Z., Moons, L., Carmeliet, P., Castellino, F.J., Collen, D., and Rosen, E.D. (2000) Blood coagulation factor X deficiency causes partial embryonic lethality and fatal neonatal bleeding in mice Thromb Haemost 83, 185-90.
223. Gailani, D., Lasky, N.M., and Broze, G.J., Jr. (1997) A murine model of factor XI deficiency Blood Coagul Fibrinolysis 8, 134-44.
224. Toomey, J.R., Kratzer, K.E., Lasky, N.M., and Broze, G.J., Jr. (1997) Effect of tissue factor deficiency on mouse and tumor development Proc Natl Acad SciUSA 94, 6922-6.
225. Darrow, A.L., Fung-Leung, W.P., Ye, R.D., Santulli, R.J., Cheung, W.M., Derian, C.K., Burns, C.L., Damiano, B.P., Zhou, L., Keenan, C.M., Peterson, P.A., and Andrade- Gordon, P. (1996) Biological consequences of thrombin receptor deficiency in mice Thromb Haemost 76, 860-6.
226. Healy, A.M., Hancock, W.W., Christie, P.D., Rayburn, H.B., and Rosenberg, R.D. (1998) Intravascular coagulation activation in a murine model of thrombomodulin deficiency: Effects of lesion size, age, and hypoxia on fibrin deposition Blood 92, 4188-97.
227. Weiler-Guettler, H., Christie, P.D., Beeler, D.L., Healy, A.M., Hancock, W.W., Rayburn, H., Edelberg, J.M., and Rosenberg, R.D. (1998) A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state J Clin Invest 101, 1983-91.
228. Jalbert, L.R., Rosen, E.D., Moons, L., Chan, J.C., Carmeliet, P., Collen, D., and Castellino, F.J. (1998) Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice J Clin Invest 102, 1481-8.
229. Lijnen,H.R., Okada, K., Matsuo, O., Collen, D., and Dewerchin, M. (1999) Alpha2- antiplasmin gene deficiency in mice is associated with enhanced fibrinolytic potential without overt bleeding Blood 93, 2274-81.
230. Eitzman, D.T., McCoy, R.D., Zheng, X., Fay, W.P., Shen, T., Ginsburg, D., and Simon, R.H. (1996) Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene J Clin Invest 97, 232-7.
231. Erickson, L.A., Fici, G.J., Lund, J.E., Boyle, T.P., Polites, H.G., and Marotti, K.R. (1990) Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene Nature 346, 74-6.
232. Pinsky, D.J., Liao, H., Lawson, C.A., Yan, S.F., Chen, J., Carmeliet, P., Loskutoff, D.J., and Stern, D.M. (1998) Coordinated induction of plasminogen activator inhibitor-1 (PAI-1) and inhibition of plasminogen activator gene expression by hypoxia promotes pulmonary vascular fibrin deposition J Clin Invest 102, 919-28.
233. Eitzman, D.T., Westrick, R.J., Nabel, E.G., and Ginsburg, D. (2000) Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice Blood 95, 577-80.
234. Zheng, X., Saunders, T.L., Camper, S.A., Samuelson, L.C., and Ginsburg, D. (1995) Vitronectin is not essential for normal mammalian development and fertility Proc Natl Acad Sci USA 92, 12426-30.
235. Heckel, J.L., Sandgren, E.P., Degen, J.L., Palmiter, R.D., and Brinster, R.L. (1990) Neonatal bleeding in transgenic mice expressing urokinase-type plasminogen activator Cell 62, 447-56.
236. Bugge, T.H., Flick, M.J., Danton, M.J., Daugherty, C.C., Romer, J., Dano, K., Carmeliet, P., Collen, D., and Degen, J.L. (1996) Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator Proc Natl Acad Sci USA 93, 5899-904.
237. Bugge, T.H., Suh, T.T., Flick, M.J., Daugherty, C.C., Romer, J., Solberg, H., Ellis, V., Dano, K., and Degen, J.L. (1995) The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility J Biol Chem270, 16886-94.
238. Dewerchin, M., Nuffelen, A.V., Wallays, G., Bouche, A., Moons, L., Carmeliet, P., Mulligan, R.C., and Collen, D. (1996) Generation and characterization of urokinase receptor-deficient mice J Clin Invest 97, 870-8.
239. Piguet, P.F., Da Laperrousaz, C., Vesin, C., Tacchini-Cottier, F., Senaldi, G., and Grau, G.E. (2000) Delayed mortality and attenuated thrombocytopenia associated with severe malaria in urokinase- and urokinase receptor-deficient mice Infect Immun 68, 3822-9.
240. Ware, J., Russell, S., and Ruggeri, Z.M. (2000) Generation and rescue of a murine model of platelet dysfunction: The Bernard- Soulier syndrome Proc Natl Acad Sci USA 97, 2803-8.
241. Ramakrishnan, V., Reeves, P.S., DeGuzman, F., Deshpande, U., Ministri-Madrid, K., DuBridge, R.B., and Phillips, D.R. (1999) Increased thrombin responsiveness in platelets from mice lacking glycoprotein V Proc Natl Acad Sci USA 96, 13336-41.
242. Tronik-Le Roux, D., Roullot, V., Poujol, C., Kortulewski, T., Nurden, P., and Marguerie, G. (2000) Thrombasthenic mice generated by replacement of the integrin alpha(IIb) gene: Demonstration that transcriptional activation of this megakaryocytic locus precedes lineage commitment Blood 96, 1399-408.
243. McHugh, K.P., Hodivala-Dilke, K., Zheng, M.H., Namba, N., Lam, J., Novack, D., Feng, X., Ross, F.P., Hynes, R.O., and Teitelbaum, S.L. (2000) Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts J Clin Invest 105, 433-40.
244. Nieswandt, B., Brakebusch, C., Bergmeier, W., Schulte, V., Bouvard, D., Mokhtari- Nejad, R., Lindhout, T., Heemskerk, J.W., Zirngibl, H., and Fassler, R. (2001) Glycoprotein VI but not alpha2beta1 integrin is essential for platelet interaction with collagen EMBO J 20, 2120-30.
245. Ni, H., Denis, C.V., Subbarao, S., Degen, J.L., Sato, T.N., Hynes, R.O., and Wagner, D.D. (2000) Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen J Clin Invest 106, 385-92.
246. Murata, T., Ushikubi, F., Matsuoka, T., Hirata, M., Yamasaki, A., Sugimoto, Y., Ichikawa, A., Aze, Y., Tanaka, T., Yoshida, N., Ueno, A., Oh-ishi, S., and Narumiya, S. (1997) Altered pain perception and inflammatory response in mice lacking prostacyclin receptor Nature 388, 678-82.
247. Duncan, G.S., Andrew, D.P., Takimoto, H., Kaufman, S.A., Yoshida, H., Spellberg, J., Luis de la Pompa, J., Elia, A., Wakeham, A., Karan-Tamir, B., Muller, W.A., Senaldi, G., Zukowski, M.M., and Mak, T.W. (1999) Genetic evidence for functional redundancy of platelet/endothelial cell adhesion molecule-1 (PECAM-1): CD31- deficient mice reveal PECAM-1-dependent and PECAM-1-independent functions J Immunol 162, 3022-30.
248. Mahooti, S., Graesser, D., Patil, S., Newman, P., Duncan, G., Mak, T., and Madri, J.A. (2000) PECAM-1 (CD31) expression modulates bleeding time in vivo Am J Pathol 157, 75-81.
249. Huang, L., Kuo, Y.M., and Gitschier, J. (1999) The pallid gene encodes a novel, syntaxin 13-interacting protein involved in platelet storage pool deficiency Nat Genet 23, 329-32.
250. Ohlmann, P., Eckly, A., Freund, M., Cazenave, J.P., Offermanns, S., and Gachet, C. (2000) ADP induces partial platelet aggregation without shape change and potentiates collagen-induced aggregation in the absence of Galphaq Blood 96, 2134-9.
251. Wang, D., Feng, J., Wen, R., Marine, J.C., Sangster, M.Y., Parganas, E., Hoffmeyer, A., Jackson, C.W., Cleveland, J.L., Murray, P.J., and Ihle, J.N. (2000) Phospholipase Cgamma2 is essential in the functions of B cell and several Fc receptors Immunity 13, 25-35.
252. Enjyoji, K., Sevigny, J., Lin, Y., Frenette, P.S., Christie, P.D., Esch, J.S., 2nd, Imai, M., Edelberg, J.M., Rayburn, H., Lech, M., Beeler, D.L., Csizmadia, E., Wagner, D.D., Robson, S.C., and Rosenberg, R.D. (1999) Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation Nat Med 5, 1010-7.
253. Massberg, S., Sausbier, M., Klatt, P., Bauer, M., Pfeifer, A., Siess, W., Fassler, R., Ruth, P., Krombach, F., and Hofmann, F. (1999) Increased adhesion and aggregation of platelets lacking cyclic guanosine 3,5- monophosphate kinase I J Exp Med 189, 1255-64.
254. Aszodi, A., Pfeifer, A., Ahmad, M., Glauner, M., Zhou, X.H., Ny, L., Andersson, K.E., Kehrel, B., Offermanns, S., and Fassler, R. (1999) The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function EMBO J 18, 37-48.
255. Hauser, W., Knobeloch, K.P., Eigenthaler, M., Gambaryan, S., Krenn, V., Geiger, J., Glazova, M., Rohde, E., Horak, I., Walter, U., and Zimmer, M. (1999) Megakaryocyte hyperplasia and enhanced agonist-induced platelet activation in vasodilator-stimulated phosphoprotein knockout mice Proc Natl Acad Sci USA 96, 8120-5.
256. Chen, X.S., Sheller, J.R., Johnson, E.N., and Funk, C.D. (1994) Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene Nature 372, 179-82.
257. Johnson, E.N., Brass, L.F., and Funk, C.D. (1998) Increased platelet sensitivity to ADP in mice lacking platelet-type 12- lipoxygenase Proc Nat Acad Sci USA 95, 3100-5.
258. Lawler, J., Sunday, M., Thibert, V., Duquette, M., George, E.L., Rayburn, H., and Hynes, R.O. (1998) Thrombospondin- 1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia J Clin Invest 101, 982-92.
259. Schumacher, W.A., Steinbacher, T.E., Megill, J.R., and Durham, S.K. (1996) A ferret model of electrical-induction of arterial thrombosis that is sensitive to aspirin J Pharmacol Toxicol Methods 35, 3-10.
260. Sloan, M.A., and Gore, J.M. (1992) Ischemic stroke and intracranial hemorrhage following thrombolytic therapy for acute myocardial infarction: A risk-benefit analysis Am J Cardiol 69, 21A-38A.
261. Stieg, P.E., and Kase, C.S. (1998) Intracranial hemorrhage: Diagnosis and emergency management Neurolog Clin 16, 373-90.
262. Bernardi, M.M., Califf, R.M., Kleiman, N., Ellis, S.G., and Topol, E.J. (1993) Lack of usefulness of prolonged bleeding times in predicting hemorrhagic events in patients receiving the 7E3 glycoprotein IIb/IIIa platelet antibody. The TAMI Study Group Am J Cardiol 72, 1121-5.
263. Bick, R.L. (1995) Laboratory evaluation of platelet dysfunction Clin Lab Med 15, 1-38.
264. Rodgers, R.P., and Levin, J. (1990) A critical reappraisal of the bleeding time Semin Thromb Hemost 16, 1-20.
265. (1996) A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The global use of strategies to open occluded coronary arteries (GUSTO) IIb investigators N Engl J Med 335, 775-82.
266. Antman, E.M. (1996) Hirudin in acute myocardial infarction. Thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial Circulation 94, 911-21.
267. Cox, D., Motoyama, Y., Seki, J., Aoki, T., Dohi, M., and Yoshida, K. (1992) Pentamidine: A non-peptide GPIIb/IIIa antagonist- in vitro studies on platelets from humans and other species Thromb Haemost 68, 731-6.
268. Bostwick, J.S., Kasiewski, C.J., Chu, V., Klein, S.I., Sabatino, R.D., Perrone, M.H., Dunwiddie, C.T., Cook, J.J., and Leadley, R.J., Jr. (1996) Anti-thrombotic activity of RG13965, a novel platelet fibrinogen receptor antagonist Thromb Res 82, 495-507.
269. Cook, N.S., Zerwes, H.G., Tapparelli, C., Powling, M., Singh, J., Metternich, R., and Hagenbach, A. (1993) Platelet aggregation and fibrinogen binding in human, rhesus monkey, guinea-pig, hamster and rat blood: Activation by ADP and a thrombin receptor peptide and inhibition by glycoprotein IIb/IIIa antagonists Thromb Haemost 70, 531-9.
270. Panzer-Knodle, S., Taite, B.B., Mehrotra, D.V., Nicholson, N.S., and Feigen, L.P. (1993) Species variation in the effect of glycoprotein IIb/IIIa antagonists on inhibition of platelet aggregation J Pharmacol Toxicol Methods 30, 47-53.
271. Cook, J.J., Holahan, M.A., Lyle, E.A., Ramjit, D.R., Sitko, G.R., Stranieri, M.T., Stupienski, R.F., 3rd, Wallace, A.A., Hand, E.L., Gehret, J.R., Kothstein, T., Drag, M.D., McCormick, G.Y., Perkins, J.J., Ihle, N.C., Duggan, M.E., Hartman, G.D., Gould, R.J., and Lynch, J.J., Jr. (1996) Nonpeptide glycoprotein IIb/IIIa inhibitors. 8. Antiplatelet activity and oral antithrombotic efficacy of L-734,217 J Pharmacol Exp Therap 278, 62-73.
272. Nutt, E.M., Jain, D., Lenny, A.B., Schaffer, L., Siegl, P.K., and Dunwiddie, C.T. (1991) Purification and characterization of recombinant antistasin: A leech-derived inhibitor of coagulation factor Xa Arch Biochem Biophys 285, 37-44.
273. Taniuchi, Y., Sakai, Y., Hisamichi, N., Kayama, M., Mano, Y., Sato, K., Hirayama, F., Koshio, H., Matsumoto, Y., and Kawasaki, T. (1998) Biochemical and pharmacological characterization of YM-60828, a newly synthesized and orally active inhibitor of human factor Xa Thromb Haemost 79, 543-8.
274. Tidwell, R.R., Webster, W.P., Shaver, S.R., and Geratz, J.D. (1980) Strategies for anticoagulation with synthetic protease inhibitors. Xa inhibitors versus thrombin inhibitors Thromb Res 19, 339-49.
275. Kararli, T.T. (1995) Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals Biopharmaceut Drug Dispos 16, 351-80.
276. Sanderson, P.E., Cutrona, K.J., Dorsey, B.D., Dyer, D.L., McDonough, C.M., Naylor- Olsen, A.M., Chen, I.W., Chen, Z., Cook, J.J., Gardell, S.J., Krueger, J.A., Lewis, S.D., Lin, J.H., Lucas, B.J., Jr., Lyle, E.A., Lynch, J.J., Jr., Stranieri, M.T., Vastag, K., Shafer, J.A., and Vacca, J.P. (1998) L-374,087, an efficacious, orally bioavailable, pyridinone acetamide thrombin inhibitor Bioorg Med Chem Lett 8, 817-22.
277. Sun, W.Y., Witte, D.P., Degen, J.L., Colbert, M.C., Burkart, M.C., Holmback, K., Xiao, Q., Bugge, T.H., and Degen, S.J. (1998) Prothrombin deficiency results in embryonic and neonatal lethality in mice Proc Natl Acad Sci USA 95, 7597-602.
278. Xue, J., Wu, Q., Westfield, L.A., Tuley, E.A., Lu, D., Zhang, Q., Shim, K., Zheng, X., and Sadler, J.E. (1998) Incomplete embryonic lethality and fatal neonatal hemorrhage caused by prothrombin deficiency in mice Proc Natl Acad Sci USA 95, 7603-7.
279. Matsuo, O., Rijken, D.C., and Collen, D. (1981) Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolus Nature 291, 590-1.
280. Collen, D., Topol, E.J., Tiefenbrunn, A.J., Gold, H.K., Weisfeldt, M.L., Sobel, B.E., Leinbach, R.C., Brinker, J.A., Ludbrook, P.A., and Yasuda, I., et al. (1984) Coronary thrombolysis with recombinant human tissue-type plasminogen activator: A prospective, randomized, placebo-controlled trial Circulation 70, 1012-7.
281. Topol, E.J., Califf, R.M., Weisman, H.F., Ellis, S.G., Tcheng, J.E., Worley, S., Ivanhoe, R., George, B.S., Fintel, D., and Weston, M., et al. (1994) Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months. The EPIC investigators Lancet 343, 881-6.
282. Lynch, J.J., Jr., Sitko, G.R., Lehman, E.D., and Vlasuk, G.P. (1995) Primary prevention of coronary arterial thrombosis with the factor Xa inhibitor rTAP in a canine electrolytic injury model Thromb Haemost 74, 640-5.
283. (1998) Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet receptor inhibition in ischemic syndrome management in patients limited by unstable signs and symptoms (PRISM-PLUS) study investigators N Engl J Med 338, 1488-97.
284. Ohman, E.M., Kleiman, N.S., Gacioch, G., Worley, S.J., Navetta, F.I., Talley, J.D., Anderson, H.V., Ellis, S.G., Cohen, M.D., Spriggs, D., Miller, M., Kereiakes, D., Yakubov, S., Kitt, M.M., Sigmon, K.N., Califf, R.M., Krucoff, M.W., and Topol, E.J. (1997) Combined accelerated tissueplasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI investigators Circulation 95, 846-54.
285. Cohen, M., Demers, C., Gurfinkel, E.P., Turpie, A.G., Fromell, G.J., Goodman, S., Langer, A., Califf, R.M., Fox, K.A., Premmereur, J., and Bigonzi, F. (1998) Low-molecular-weight heparins in non-STsegment elevation ischemia: The ESSENCE trial. Efficacy and safety of subcutaneous enoxaparin versus intravenous unfractionated heparin, in non-Q-wave coronary events Am J Cardiol 82, 19L-24L.
286. Agnelli, G., Pascucci, C., Cosmi, B., and Nenci, G.G. (1990) The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits Thromb Haemost 63, 204-7.
287. Eriksson, B.I., Wille-Jorgensen, P., Kalebo, P., Mouret, P., Rosencher, N., Bosch, P., Baur, M., Ekman, S., Bach, D., Lindbratt, S., and Close, P. (1997) A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement N Engl J Med 337, 1329-35.
288. Fitzgerald, D.J., Wright, F., and FitzGerald, G.A. (1989) Increased thromboxane biosynthesis during coronary thrombolysis. Evidence that platelet activation and thromboxane A2 modulate the response to tissuetype plasminogen activator in vivo Circ Res 65, 83-94.
289. Gold, H.K., Torres, F.W., Garabedian, H.D., Werner, W., Jang, I.K., Khan, A., Hagstrom, J.N., Yasuda, T., Leinbach, R.C., and Newell, J.B., et al. (1993) Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris J Am Coll Cardiol 21, 1039-47.